Deutsche Bank reiterated their neutral rating on shares of GlaxoSmithKline (NYSE:GSK) in a research note released on Monday.
Other analysts have also issued research reports about the stock. UBS reiterated a buy rating on shares of GlaxoSmithKline in a research note on Monday, January 15th. Zacks Investment Research upgraded shares of GlaxoSmithKline from a hold rating to a buy rating and set a $40.00 target price for the company in a research note on Tuesday, January 2nd. TheStreet lowered shares of GlaxoSmithKline from a b- rating to a c rating in a research note on Wednesday, February 7th. Morgan Stanley upgraded shares of GlaxoSmithKline from an underweight rating to an equal weight rating in a research note on Thursday, March 22nd. Finally, ValuEngine lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Sunday, December 31st. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the stock. GlaxoSmithKline currently has an average rating of Hold and a consensus target price of $40.46.
Shares of GSK stock opened at $40.62 on Monday. The firm has a market cap of $101,607.21, a price-to-earnings ratio of 14.10, a price-to-earnings-growth ratio of 2.28 and a beta of 0.84. The company has a debt-to-equity ratio of 4.09, a current ratio of 0.60 and a quick ratio of 0.39. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $44.53.
GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The firm had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion. analysts forecast that GlaxoSmithKline will post 2.94 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, April 12th. Investors of record on Friday, February 23rd were issued a $0.633 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.23%. The ex-dividend date of this dividend was Thursday, February 22nd. GlaxoSmithKline’s payout ratio is 87.85%.
Several large investors have recently modified their holdings of the stock. Renaissance Technologies LLC boosted its holdings in shares of GlaxoSmithKline by 2.4% in the 4th quarter. Renaissance Technologies LLC now owns 9,668,300 shares of the pharmaceutical company’s stock worth $342,935,000 after buying an additional 230,600 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of GlaxoSmithKline by 55.5% in the 4th quarter. Two Sigma Advisers LP now owns 5,074,642 shares of the pharmaceutical company’s stock worth $179,998,000 after buying an additional 1,811,400 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of GlaxoSmithKline by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 2,388,168 shares of the pharmaceutical company’s stock worth $84,708,000 after buying an additional 457,276 shares during the last quarter. Brandes Investment Partners LP boosted its holdings in shares of GlaxoSmithKline by 6.1% in the 4th quarter. Brandes Investment Partners LP now owns 2,262,946 shares of the pharmaceutical company’s stock worth $80,267,000 after buying an additional 130,182 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in shares of GlaxoSmithKline by 259.7% in the 4th quarter. Millennium Management LLC now owns 1,825,451 shares of the pharmaceutical company’s stock worth $64,749,000 after buying an additional 1,318,012 shares during the last quarter. 10.97% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/13/glaxosmithkline-gsk-earns-neutral-rating-from-deutsche-bank.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.